3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
8
Active not recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
438
Carboplatin
322
Nivolumab
286
Cyclophosphamide
280
Specimen Handling
257
Cisplatin
252
Paclitaxel
249
Magnetic Resonance Spectroscopy
248
Radiotherapy
217
Gemcitabine
180
Dexamethasone
180
Biopsy
177
durvalumab
167
atezolizumab
148
Rituximab
138
Lenalidomide
134
Doxorubicin
134
Docetaxel
130
Bevacizumab
129
Ipilimumab
125
Radiation
118
Capecitabine
117
Pemetrexed
113
Oxaliplatin
112
Etoposide
111
Radiosurgery
109
venetoclax
108
Fluorouracil
108
fludarabine
106
Prednisone
97
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Interventional
×
tisotumab vedotin
×
Clear all
NCT06459180
2026-05-27
TroFuse-020
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
686 enrolled
NCT03485209
2026-04-20
innovaTV 207
Seagen Inc.
Phase 2
Active not recruiting
350 enrolled